Patents by Inventor Dror ALISHEKEVITZ

Dror ALISHEKEVITZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for decreasing soluble immune receptor CD28
    Patent number: 12139534
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 12, 2024
    Assignee: BIOND BIOLOGICS LTD.
    Inventors: Motti Hakim, Dror Alishekevitz, Dana Haves Ziv, Edna Meilin, Yair Sapir, Avidor Shulman, Tehila Ben-Moshe, Ilana Mandel
  • METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
    Publication number: 20240309094
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Application
    Filed: June 6, 2024
    Publication date: September 19, 2024
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Dana HAVES ZIV, Edna MEILIN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE, Ilana MANDEL
  • Antibodies against ILT2 and use thereof
    Patent number: 12071479
    Abstract: The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: August 27, 2024
    Assignee: BIOND BIOLOGICS LTD.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY
    Publication number: 20230221325
    Abstract: Methods of determining suitability of a subject suffering from cancer or at risk of cancer relapse to receive treatment comprising an agent that reduces sCD28 levels are provided. Methods of treating a subject suffering from cancer or at risk of cancer relapse comprising administering an anti-PD-1/PD-L1 immunotherapy, measuring soluble CD28 levels in a subject, and administering an agent that reduces sCD28 levels to a subject whose sCD28 levels increased are also provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: Anna FRIDMAN-DROR, Tal GABAY, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Motti HAKIM
  • SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY
    Publication number: 20230035730
    Abstract: Methods of diagnosing and predicting cancer relapse comprising measuring soluble CD28 levels in a subject, wherein an increase in soluble CD28 is indicative of cancer relapse or imminent cancer relapse, are provided. Methods of determining response to PD-1/PD-L1 based immunotherapy in a subject in need thereof, comprising measuring sCD28 levels in a subject undergoing PD-1/PD-L1 based immunotherapy at at least two time points wherein a decrease indicates response and an increase indicates lack of response, are also provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: February 2, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Orit SHILOVIZKY, Dror ALISHEKEVITZ, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • SMALL SHEDDING BLOCKING AGENTS
    Publication number: 20220169732
    Abstract: Agents that are less than 100 kilodaltons, bind a membranal immune receptor on a surface of a cell and inhibit proteolytic cleavage of the immune receptor are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 2, 2022
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN, Yair SAPIR
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220153836
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 19, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • A METHOD FOR IMMUNOSUPPRESSION
    Publication number: 20220153845
    Abstract: The present invention, in some embodiments thereof, is directed to a method for suppressing an immune response in a subject, including administering to the subject a therapeutically effective amount of an agent having specific binding affinity to a soluble immune receptor.
    Type: Application
    Filed: March 12, 2020
    Publication date: May 19, 2022
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Edna MEILIN, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20220048991
    Abstract: The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 17, 2022
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • Antibodies against ILT2
    Patent number: 11236162
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 1, 2022
    Assignee: Biond Biologies Ltd.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • Antibodies Against ILT2 and Use Thereof
    Publication number: 20210277112
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 9, 2021
    Applicant: Biond Biologics Ltd.
    Inventors: Ilana MANDEL, Tsuri PERETZ, Dana HAVES ZIV, Ilana GOLDSHTEIN, Dror ALISHEKEVITZ, Anna FRIDMAN-DROR, Motti HAKIM, Avidor SHULMAN, Yair SAPIR, Tehila BEN-MOSHE
  • METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
    Publication number: 20210047411
    Abstract: Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 18, 2021
    Inventors: Motti HAKIM, Dror ALISHEKEVITZ, Dana HAVES ZIV, Edna MEILIN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE, Ilana MANDEL